抑制NF-κB激活途径治疗IBD的进展

Progress in blockade of NF-κB activation to treat inflammatory bowel disease

IBD患者肠道黏膜免疫反应异常,NF-κB是参与调控肠道免疫炎性反应的关键因子之一。现已证明,多种IBD临床治疗用药,如糖皮质激素、5-氨基水杨酸、抑制性细胞因子等的药理作用均与抑制NF-κB激活途径有关。此文从NF-κB在IBD发病机制上的作用入手,总结了目前在营养素治疗、激素治疗、中药治疗及其他新药对抑制NF-κB激活途径治疗IBD的研究。

In patients with IBD the mucosal immune response is derailed. The nuclear factor kappaB（NF-κB） is a key regulator of the immune and inflammatory responses in the gut. It has been proved that drugs like corticosteroids, mesalazine and inhibitory cytokines can prevent the activation of NF-κB. This article is starting from the function of NF -κB in the pathogenesis of IBD , overviewed the new medicine research in blockade of NF-κB activation to treat this disease, including the nourishment treatment, the hormone treatment, the Chinese herbal medicine treatment and other new drugs.